Hexocyclium
An anticholinergic medication formerly used to treat peptic ulcer disease by reducing gastric acid secretion and gastrointestinal motility through blockade of muscarinic receptors. It belongs to the class of antispasmodic agents that reduce gut cramping and secretions. It has been replaced by more effective and better-tolerated therapies such as proton pump inhibitors.
Molekularmasse
317,5000 g/mol
LogP
3,10
TPSA
23,50 Ų
Lipinski-Regel der Fünf
Bestanden
Wirkmechanismus
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid …
2D-Struktur
Cite this structure
Embed this structure
SMILES
C[N+]1(C)CCN(CC(O)(c2ccccc2)C2CCCCC2)CC1
InChI
InChI=1S/C20H33N2O/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3/q+1
Molecular Formula
C20H33N2O+
HBD / HBA
1 / 2
Rotierbare Bindungen
4
Schwere Atome
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An anticholinergic medication formerly used to treat peptic ulcer disease by reducing gastric acid secretion and gastrointestinal motility through blockade of muscarinic receptors. It belongs to the class of antispasmodic agents that reduce gut cramping and secretions. It has been replaced by more effective and better-tolerated therapies such as proton pump inhibitors.
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) on the apical surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, producing profound and sustained acid suppression.
Yes, Hexocyclium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201325. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 24199. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hexocyclium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hexocyclium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hexocyclium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hexocyclium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hexocyclium"></drugfyi-drug>